Atossa Genetics (ATOS) Given a $5.00 Price Target at Maxim Group

Maxim Group set a $5.00 target price on Atossa Genetics (NASDAQ:ATOS) in a research report sent to investors on Monday. The firm currently has a buy rating on the stock.

Shares of ATOS stock opened at $1.30 on Monday. Atossa Genetics has a 1-year low of $1.12 and a 1-year high of $10.68.

Atossa Genetics (NASDAQ:ATOS) last announced its earnings results on Tuesday, November 13th. The company reported ($0.64) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.65) by $0.01. Research analysts predict that Atossa Genetics will post -4.08 earnings per share for the current year.



Atossa Genetics Company Profile

Atossa Genetics Inc a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions.

Recommended Story: Return on Investment (ROI) Defined, Explained

Receive News & Ratings for Atossa Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply